Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · see citing works

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · see citing works

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109 · see citing works

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · see citing works

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730 · see citing works

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726 · see citing works

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203 · see citing works

Epidermal growth factor-related peptides and their receptors in human malignancies.

Salomon, D., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical reviews in oncology/hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,860 · see citing works

Cetuximab for the Treatment of Colorectal Cancer

Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · see citing works

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815 · see citing works

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752 · see citing works

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712 · see citing works

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,703 · see citing works

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Bokemeyer, C., Bondarenko, I., Makhson, A. M., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,629 · see citing works

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581 · see citing works

Cetuximab in the treatment of colorectal cancer.

Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518 · see citing works

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V. A., Hirsh, V., Leighl, N. B., Mezger, J. M., Archer, V. R., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,500 · see citing works

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · see citing works

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453 · see citing works

American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003

Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W. T., Smith, T. J., Baker, S., Olak, J., Stover, D. E., Strawn, J. R., Turrisi, A. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,411 · see citing works

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346 · see citing works

Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer

Mendelsohn, J. M., & Baselga, J. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,257 · see citing works

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Kim, E. S., Hirsh, V., Mok, T. S. K., Socinski, M. A., Gervais, R., Wu, Y.-L. L. C., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,241 · see citing works

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

Kelly, K. L., Crowley, J. J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,122 · see citing works

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081 · see citing works

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

Vermorken, J. B., Trigo, J. M., Hitt, R., Koralewski, P., Díaz‐Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7447 · Cited by 1,008 · see citing works

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 940 · see citing works

Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

Fossella, F. V., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V. A., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 938 · see citing works

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Rosa, F. D., Milanowski, J., Karnicka-Mlodkowski, H., Pešek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 875 · see citing works

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations

Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820 · see citing works

Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument

Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750 · see citing works

Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D. S., Hölscher, A. H., & Danenberg, P. V. (2001) · PubMed · Cited by 452 · see citing works

Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435 · see citing works

Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.

Evans, W. K. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.08.002 · Cited by 405 · see citing works

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Herbst, R. S., O’Neill, V., Fehrenbacher, L., Belani, C. P., Bonomi, P., Hart, L. L., Melnyk, O. O., Ramies, D. A., Lin, M., & Sandler, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3026 · Cited by 394 · see citing works

Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975

Smit, E. F., van Meerbeeck, J. P. A. M., LIANES, P., Debruyne, C., LeGrand, C. C., Schramel, F. M. N. H., Smit, H. J. M., Gaafar, R. M., Biesma, B., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.195 · Cited by 350 · see citing works

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

Khambata‐Ford, S., Harbison, C. T., Hart, L. L., Awad, M., Xu, L., Horak, C. E., Dakhil, S. R., Hermann, R. C., Lynch, T. J., & Weber, M. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2890 · Cited by 265 · see citing works

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Rosell, R., Robinet, G., Szczęsna, A., Ramlau, R., Constenla, M., Mennecier, B., Pfeifer, W., O'Byrne, K. J., Welte, T., Kolb, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm474 · Cited by 258 · see citing works

Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non–Small-Cell Lung Cancer

Thienelt, C. D., Bunn, P. A., Hanna, N. H., Rosenberg, A., Needle, M. N., Long, M. E., Gustafson, D. L., & Kelly, K. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1997 · Cited by 203 · see citing works

Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D. H., Alam, Y., Kreisman, H., Graze, P. R., Maher, J. F., Ross, H. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0856 · Cited by 194 · see citing works

Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinoma

Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H., & Fujii, H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22370 · Cited by 174 · see citing works

The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture

DeVita, V. T. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1 · Cited by 164 · see citing works

Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer

Robert, F., Blumenschein, G., Herbst, R. S., Fossella, F. V., Tseng, J. E., Saleh, M. N., & Needle, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1438 · Cited by 150 · see citing works

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)

Fukuoka, M., Wu, Y., Thongprasert, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8006 · Cited by 119 · see citing works

What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)

Cella, D. F., Paul, D., Yount, S., Winn, R. J., Chang, C., Banik, D., & Weeks, J. C. (2003) · Cancer Investigation · doi:10.1081/cnv-120022366 · Cited by 107 · see citing works

Thymic Carcinoma: 30 Cases at a Single Institution

Yano, M., Sasaki, H., Yokoyama, T., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181653c71 · Cited by 105 · see citing works

A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342

Herbst, R. S., Chansky, K., Kelly, K. L., Atkins, J. N., Davies, A. M., Dakhil, S. R., Albain, K. S., Kim, E. S., Crowley, J. J., & Gandara, D. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7545 · Cited by 53 · see citing works

The Validity and Clinical Utility of Symptom Monitoring in Advanced Lung Cancer: A Literature Review

Soni, M., Cella, D. F., Masters, G. A., Burch, S. P., Heyes, A., & Silberman, C. (2002) · Clinical Lung Cancer · doi:10.3816/clc.2002.n.022 · Cited by 25 · see citing works

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083 · see citing works

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850 · see citing works

Delivering affordable cancer care in high-income countries

Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718 · see citing works

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · see citing works

The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review

Aerts, H. J. W. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2631 · Cited by 669 · see citing works

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Paz-Ares, L., Mezger, J., Ciuleanu, T. E., Fischer, J. R., von Pawel, J., Provencio, M., Kazarnowicz, A., Losonczy, G., de Castro, G., Szczesna, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70046-x · Cited by 133 · see citing works

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Cavazzoni, A., Alfieri, R. R., Cretella, D., Saccani, F., Ampollini, L., Galetti, M., Quaini, F., Graiani, G., Madeddu, D., Mozzoni, P., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-91 · Cited by 44 · see citing works

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies

Perez, R. P., Chen, E. X., Beck, J. T., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.519 · Cited by 6 · see citing works

Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer

Sun, L., Candelieri-Surette, D., Anglin-Foote, T. R., et al. (2022) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2022.2791 · Cited by 42 · see citing works

進行・再発子宮体部漿液性腺癌に対するCarboplatin／Taxane療法の有効性に関する検討

松浦, 拓., & ほか (2016) · 癌と化学療法

ACTR-08. A PHASE II STUDY OF APATINIB PLUS TEMOZOLOMIDE IN ADULTS WITH REFRACTORY RECURRENT HIGH-GRADE GLIOMAS

Zhang, J., Ge, J., & Li, C. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy148.043

A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma

Butowski, N. A., Prados, M. D., Lamborn, K. R., Larson, D. A., Sneed, P. K., Wara, W. M., Malec, M. K., Rabbitt, J. E., Page, M., & Chang, S. M. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.023 · Cited by 50 · see citing works